Fig. 6: Treatment with Bcl2 inhibitor in vivo improves surivial of leukemic mice with TKI resistance. | Cell Death & Disease

Fig. 6: Treatment with Bcl2 inhibitor in vivo improves surivial of leukemic mice with TKI resistance.

From: Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome

Fig. 6

In vivo analysis of resistant CEP2A-R cells xenografted into BALB/c mice shows a significantly increased survival in cohorts treated with ABT199 (A). While no change in the body weight or liver weight was seen at the time of sacrifice, spleen weights and total white blood cell counts were reduced in the treated mice (B). Blood smears from drug treated and control mice are shown in C and analysis of the GFP+ leukemic cells in the peripheral blood (D) shows a highly significant reduction in the mice treated with ABT199. Images were captured at ×10 magnification using an EVOS FL Auto microscope system. Student’s t-test was used for statistical comparison between groups. N = 5 in each group. **p < 0.01; ***p < 0.001; ns not significant.

Back to article page